Pharmacogenetic testing is relatively easy and minimally invasive for patients, involving either a simple blood draw or saliva collection. The test is to identify variations in genes coding for proteins that are responsible for drug disposition, especially drug-metabolizing enzymes. The most common type of genetic variation that exist in these genes is a change at one nucleotide in the DNA sequence of the gene called a single nucleotide variation (SNV). These variations can alter the function of the respective enzyme and subsequently alter a person’s ability to metabolize or transport certain drugs. Often a person’s pharmacogenetic test results are reported as a phenotype based on their genotype. The predicted phenotypes, also called the individual’s “metabolizer status”, are classified as poor, intermediate/reduced, extensive, rapid, or ultra-rapid depending on which genetic variants (alternative alleles) are present. As part of the reporting, an asterisk-based nomenclature is used, where *1 is often the reference allele and assigned based on an individual lacking the alternative allele. To assist with interpretation of pharmacogenetic test results, the Clinical Pharmacogenetics Implementation Consortium (CPIC®) and the Dutch Pharmacogenetics Working Group (DPWG) provide guidelines, with dosing recommendations for clinically actionable pharmacogenetic test results. Currently differences in recommendations exist between the guidelines, but efforts are underway to harmonize the CPIC® and DPWG guidelines.
Nurses have a critical role to play in implementation of pharmacogenetic testing. For nurses to adopt a precision health approach and implement pharmacogenetic testing, they need to be aware of the CPIC® and DPWG guidelines and how to use the guideline recommendations. Nurses can improve the trust relationship with patients by explaining why a dosing adjustment or medication change was made based on pharmacogenetic test results. When discussing or administering medications, nurses can be alert to and verify with the prescriber if atypical drug doses are observed and regularly monitor and report adverse effects. Nurses can document patient education efforts as well as document patient response to medications.
In addition, advanced practice nurses (APNs) need to be able to assess which individuals would benefit from pharmacogenetic testing instead of testing all individuals or individuals based on receiving a prescription for a particular medication. Being able to identify those patients who would benefit the most from testing due to concerns about inefficacy or toxicity is particularly important in resource-constrained environments. Nurses are perfectly positioned in primary and specialty care settings to apply test results within the clinical context.
Every patient presents a unique challenge to the pharmacogenetic interpretation of his or her case. This makes it difficult to automate interpretation of test results and requires a knowledgeable provider to assess each patient’s genotype and medications. Pharmacogenetic test interpretation should not be confined to the medication of interest. It is also necessary to assess drug-gene interactions of existing medications to explain symptoms, inform selection of alternative treatment options, and improve efficacy of the patient’s medication profile. With sufficient knowledge and experience, all nurses will become more confident in applying pharmacogenetic results within the clinical context.